RT Journal Article
SR Electronic
T1 IMPACT smoking cessation support for people with severe mental illness in South Asia (IMPACT 4S): a protocol for a randomised controlled feasibility trial of a combined behavioural and pharmacological support intervention
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.11.03.21265856
DO 10.1101/2021.11.03.21265856
A1 Mazumdar, Papiya
A1 Zavala, Gerardo
A1 Aslam, Faiza
A1 Muliyala, Krishna Prasad
A1 Chaturvedi, Santosh Kumar
A1 Kandasamy, Arun
A1 Nizami, Asad
A1 Haq, Baha Ul
A1 Kellar, Ian
A1 Jackson, Cath
A1 Thomson, Heather
A1 McDaid, David
A1 Siddiqi, Kamran
A1 Hewitt, Catherine
A1 Siddiqi, Najma
A1 Gilbody, Simon
A1 Murthy, Pratima
A1 Mdege, Noreen
YR 2021
UL http://medrxiv.org/content/early/2021/11/04/2021.11.03.21265856.abstract
AB Introduction The prevalence of smoking is high among people living with severe mental illness (SMI). Evidence on feasibility, acceptability and effectiveness of smoking cessation interventions among smokers with SMI is lacking, particularly in low- and middle-income countries. We aim to test the feasibility and acceptability of delivering an evidence-based intervention (i.e., the IMPACT 4S intervention) that is a combination of behavioural support and smoking cessation pharmacotherapies among adult smokers with SMI in India and Pakistan. We will also test the feasibility and acceptability of evaluating the intervention in a randomised controlled trial.Methods We will conduct a parallel, open label, randomised controlled feasibility trial among 172 (86 in each country) adult smokers with SMI in India and Pakistan. Participants will be allocated 1:1 to either Brief Advice or the IMPACT 4S intervention. BA comprises a single five-minute BA session on stopping smoking. The IMPACT 4S intervention comprises behavioural support delivered in up to 15 one-to-one, face-to-face or audio/video, counselling sessions, with each session lasting between 15 and 40 minutes; nicotine gum and/or bupropion; and breath carbon monoxide monitoring and feedback. The outcomes are recruitment rates, reasons for ineligibility/non-participation/non-consent of participants, length of time required to achieve required sample size, retention in study and treatments, intervention fidelity during delivery, smoking cessation pharmacotherapy adherence and data completeness. A process evaluation will also be conducted.Ethics and dissemination The study has been approved by the University of York’s Health Sciences Research Governance Committee; Health Ministry Screening Committee, India; the Ethics Committee (Behavioural Sciences Division), NIMHANS, Bangalore, India; National Bioethics Committee Pakistan and; Institutional Research and Ethics Forum of Rawalpindi Medical University, Pakistan. Feasibility study results will be disseminated through peer-review articles, and presentations at national and international conferences and policy-engagement forums.Trial registration ISRCTN34399445 (Updated 22/03/2021), ISRCTN Registry https://www.isrctn.com/Competing Interest StatementThe authors have declared no competing interest.Clinical TrialISRCTN34399445 (Updated 22/03/2021), ISRCTN Registry https://www.isrctn.com/Funding StatementThe National Institute for Health Research (NIHR) (17/63/130) using UK aid from the UK Government to support global health research.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Research Governance Committee-Department of Health Sciences (RGC-DoHS) of University of York gave ethical approval for this work Health Ministry Screening Committee (HMSC)-India gave ethical approval for this work IRB/ the Ethics Committee Behavioural Sciences Division of NIMHANS, Bangalore, India gave ethical approval for this work IRB/National Bioethics Committee of Pakistan gave ethical approval for this work Institutional Research and Ethics Forum of Rawalpindi Medical University, Pakistan gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThis is the study protocol paper.